Delcath Systems, Inc. (DCTH) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial metrics, including high projected gross margins and revenue growth. Despite some concerns about cash flow and unclear guidance on CHOPIN's impact, the company's strategic expansion plans and focus on long-term value are promising. The Q&A section reveals a cautious but optimistic outlook, with potential catalysts like new center activations and the CHOPIN study publication. Overall, the positive financial projections and strategic growth initiatives suggest a likely positive stock price movement in the short term.
Key Financial Performance
Revenue from HEPZATO (Q4 2025) $19 million, a 38.7% increase year-over-year from $13.7 million in Q4 2024, driven by increased sales volume.
Revenue from CHEMOSAT (Q4 2025) $1.7 million, a 21.4% increase year-over-year from $1.4 million in Q4 2024, attributed to higher demand.
Full Year Revenue from HEPZATO (2025) $78.8 million, a 144% increase year-over-year from $32.3 million in 2024, due to expanded commercial efforts and site activations.
Full Year Revenue from CHEMOSAT (2025) $6.4 million, a 30.6% increase year-over-year from $4.9 million in 2024, reflecting growing adoption.
Gross Margins (Q4 2025) 85%, a slight decrease from 86% in Q4 2024, due to pricing dynamics.
Gross Margins (Full Year 2025) 86%, an increase from 83% in 2024, driven by operational efficiencies.
Research and Development Expenses (Q4 2025) $9.4 million, a 224% increase year-over-year from $2.9 million in Q4 2024, primarily due to investments in clinical trials.
Research and Development Expenses (Full Year 2025) $29.2 million, a 110% increase year-over-year from $13.9 million in 2024, reflecting expanded clinical programs.
Selling, General, and Administrative Expenses (Q4 2025) $10.5 million, a 50% increase year-over-year from $7 million in Q4 2024, driven by commercial expansion.
Selling, General, and Administrative Expenses (Full Year 2025) $43 million, a 45.3% increase year-over-year from $29.6 million in 2024, due to increased business activities.
Net Loss (Q4 2025) $1.9 million, an improvement from a $3.4 million net loss in Q4 2024, due to higher revenue.
Net Income (Full Year 2025) $2.7 million, a significant improvement from a $26.4 million net loss in 2024, driven by revenue growth and operational efficiencies.
Adjusted EBITDA (Q4 2025) $2.4 million, a decrease from $4.6 million in Q4 2024, reflecting higher operating expenses.
Adjusted EBITDA (Full Year 2025) $25.1 million, a turnaround from a $2.5 million loss in 2024, due to strong revenue performance.
Cash and Investments (End of 2025) $91 million, supported by positive operating cash flow of $8.3 million in Q4 and $22.5 million for the full year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
HEPZATO and CHEMOSAT Revenue: Revenue from HEPZATO was $78.8 million and CHEMOSAT was $6.4 million in 2025, showing significant growth from 2024.
CHOPIN Data: CHOPIN Phase II data demonstrated significant clinical benefits when PHP is sequenced with checkpoint inhibitors, improving survival rates and treatment outcomes.
Site Expansion: 28 active treatment centers in 2025, with a target of 40 by the end of 2026. New sites include MD Anderson, UT Southwestern, and Mayo Clinic Scottsdale.
Referral Networks: Efforts to develop referral networks to ensure early identification and referral of eligible patients to treatment centers.
Commercial Team Expansion: U.S. commercial team expanded into 9 regions, with dedicated managers and specialists to support site onboarding and existing accounts.
Medical Affairs Team: Revamped with new leadership and Medical Science Liaisons (MSLs) to enhance education and support for treating professionals.
Clinical Trials: Ongoing trials for metastatic colorectal cancer and breast cancer, with plans to activate 26 and 15 sites respectively by 2026.
Combination Therapy Development: Evaluating combination PHP immune checkpoint inhibitor trials for various tumor types with liver metastases, based on CHOPIN trial results.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Seasonality in site capacity: The company faces challenges in maintaining consistent site capacity due to seasonality, particularly during late summer when key personnel at treatment sites take vacations. This results in a temporary reduction in the ability to add new patients.
Variability in site activations: The pace of activating new treatment sites is expected to be variable, influenced by factors such as sales force expansion timing and the publication of CHOPIN results. This variability could impact the company's ability to meet its target of 40 active treatment centers by the end of 2026.
Education and awareness challenges: Physicians treating metastatic breast cancer patients have less experience with liver-directed therapies, requiring extensive communication and education to increase awareness and adoption of PHP treatments.
Increased R&D and SG&A expenses: The company anticipates significant increases in research and development (90%) and selling, general, and administrative expenses (50%) in 2026, which could pressure financial performance.
Pricing variability due to 340B pricing impact: The 340B pricing change is expected to result in a 10% discount on the published list price of HEPZATO kits, introducing variability in realized pricing as customer mix and 340B eligibility fluctuate.
Dependency on CHOPIN data publication: The anticipated increase in site activations and revenue growth is heavily dependent on the publication of CHOPIN Phase II data, which introduces a risk if the data publication is delayed or does not meet expectations.
Complexity in clinical trial site activation: Activating and training sites for medical device clinical trials is more complex than for conventional drug trials, potentially delaying the progress of trials for metastatic colorectal cancer and breast cancer.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: The company is guiding to total revenue of at least $100 million for the year, representing greater than a 20% increase in HEPZATO KIT procedure volume and greater than 10% growth in CHEMOSAT.
Site Activations and Capacity Expansion: The company targets 40 active treatment centers by the end of 2026, with more activations expected in the second half of 2026. Expansion of the U.S. commercial team and revamped medical affairs team will support this growth.
Seasonality Impact on Capacity: Projections for 2026 assume a similar summer seasonality pattern as 2025, with some seasonal loss of capacity in late summer due to limited REMS-certified personnel.
Clinical Development Programs: The metastatic colorectal cancer trial aims to activate nearly all 26 targeted trial sites by mid-2026, with interim data results expected in late 2027. The metastatic breast cancer trial targets 15 trial sites to be activated by late 2026, with guidance on readouts to be provided later in 2026.
CHOPIN Data Impact: The CHOPIN Phase II data is expected to increase adoption of HEPZATO as a preferred first-line liver-directed option and expand patient populations. The company is engaging key opinion leaders to support potential updates to NCCN guidelines for metastatic uveal melanoma.
R&D and SG&A Expenses: R&D expenses are expected to increase by nearly 90% in 2026, driven by ongoing clinical trials and team investments. SG&A expenses are projected to rise by nearly 50%, reflecting continued commercial expansion and general business growth.
Pricing and Gross Margins: The average selling price of HEPZATO is expected to be around $175,000 per kit in 2026, with gross margins forecasted between 84% and 87%.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends: No mention of dividends or dividend programs in the transcript.
Share Buyback Program: The company repurchased 628,572 common shares for $6 million through December 31, 2025, under the approved $25 million share buyback program. As of the date of the call, the program is ongoing.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the assumptions around the company's guidance, particularly regarding seasonality and pricing?
A:The company expects seasonality in the third quarter due to physicians and patients taking time off. They aim to temper this seasonality, expecting flat to modest growth from Q2 to Q3, with growth resuming from Q3 to Q4. Pricing increased slightly from $187.5K to $189.1K, with a more favorable mix leading to a 10% decrease in price per unit instead of the previously expected 20%.
Q:What is the difference between the HEPZATO KIT REMS site and the HEPZATO KIT site?
A:The HEPZATO KIT REMS site lists FDA-compliant centers actively treating or soon to treat patients, while the HEPZATO KIT site includes all centers accepting referrals, even if they haven't treated their first patient yet. Clinical trial centers are excluded from the REMS site unless they are also commercial centers.
Q:What is the timing and planned use of the CHOPIN study data?
A:The CHOPIN study data is expected to be published within a month. The company plans to use it to inform treating physicians, update guidelines, and highlight HEPZATO as the preferred liver-directed therapy. They will also make medical science liaisons available to answer questions.
Q:How is the company balancing clinical development with cash flow?
A:The company has a healthy balance sheet of over $90 million and is not focusing on achieving positive cash flow quarterly. They prioritize long-term value over short-term optics and may go cash flow negative in some quarters.
Q:What is the average number of treatments per patient and the interval between treatments?
A:The average number of treatments per patient is around 4 to 4.1, with an interval of approximately 7.2 to 7.3 weeks between treatments. This interval may vary slightly but is not expected to exceed 8 weeks or drop below 6 weeks.
Q:What assumptions are included in the company's guidance regarding new patient starts and site productivity?
A:The company assumes an average of 0.5 new patients per site per month, consistent with last year. They expect steady average productivity as they add more sites, with older sites reaching a cap and newer sites taking time to ramp up.
Q:What is the expected cadence of new center activations this year?
A:The company expects more center activations in the back half of the year due to increased field presence and the publication of CHOPIN results. They are expanding from 6 to 9 regions and reinvigorating their Medical Affairs Group.
Q:What are the expected R&D and SG&A expenses for the year?
A:R&D expenses are expected to increase by 20% in Q1 over Q4 and by 15% each subsequent quarter. SG&A expenses are projected to grow by nearly 50% overall this year, with a 30-40% increase in Q1 over Q4 and modest increases thereafter.
Q:What are the potential catalysts for mitigating seasonality in the third quarter?
A:Potential catalysts include the CHOPIN publication and increased site activations. However, the company remains cautious about the impact of seasonality due to capacity constraints at high-producing sites.
Q:What is the company's stance on quantifying the impact of CHOPIN on new patient starts?
A:The company declined to quantify the potential impact of CHOPIN on new patient starts, stating they would avoid making specific predictions.
Q:What is the expected discount rate for 340B hospitals, and how does it impact pricing?
A:The discount rate for 340B hospitals is 23.1%, with an effective average discount of around 10%. The company has modeled a 10% discount for the year, which is slightly better than the 12% seen in the third quarter of last year.
Q:What is the expected gross margin for 2026?
A:The company expects a gross margin of 84-87% in 2026, potentially reaching close to 90% in 2027 and beyond.
Q:What is the company's perspective on the impact of 340B pricing and competitive trials?
A:The company cannot definitively state the impact of 340B pricing on volume but believes it is not a hindrance. Competitive trials have created headwinds, but the pressure has diminished with the completion of some trials, such as the IDEA trial.
Q:What is the company's strategy for referral development and increasing patient flow?
A:The company aims to educate referring physicians about HEPZATO and connect them with treating centers. This strategy is critical for reaching patients who are not actively seeking liver-directed therapy.
Q:What is the company's approach to increasing patient volume at existing sites?
A:The company plans to address capacity constraints at high-volume centers and educate physicians at lower-share hospitals to expand patient eligibility criteria. They also aim to influence guidelines and provide data to support broader use of HEPZATO.
Q:What is the timeline for potential changes to NCCN guidelines?
A:The NCCN guidelines committee is scheduled to meet in November, but off-cycle meetings are possible. The company is fostering discussions among KOLs to drive potential changes.
Q:Review of Unclear Management Responses
A:The company avoided directly quantifying the potential impact of the CHOPIN study on new patient starts, stating they would stay away from making specific predictions. Additionally, they provided limited clarity on the exact impact of 340B pricing on volume, citing the complexity of the issue and the lack of direct feedback from hospitals.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Act
General
HEPZATO
Securities
activation expansion
breast cancer
cancer trial
capacity function
center
combination
development
disease
education
expansion field
force
launch
liver therapy
manager
melanoma publication
network
number patient
patient breast
patient site
prescribing pattern
priority KPIs
priority site
projection
publication CHOPIN
seasonality
site capacity
site month
treatment
trial site
volume record
DCTH Transcript
Delcath Systems, Inc. (DCTH) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call highlights strong financial metrics, including high projected gross margins and revenue growth. Despite some concerns about cash flow and unclear guidance on CHOPIN's impact, the company's strategic expansion plans and focus on long-term value are promising. The Q&A section reveals a cautious but optimistic outlook, with potential catalysts like new center activations and the CHOPIN study publication. Overall, the positive financial projections and strategic growth initiatives suggest a likely positive stock price movement in the short term.
Wajax Corporation (WJX:CA) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call presents a mixed picture. Equipment and product support sales slightly decreased, while ERS sales increased. The backlog and inventory decreased, but cash flows improved significantly. The Q&A reveals resilience in mining and energy, but caution in automotive and forestry. The company is comfortable with cost optimization and prepared for future demand. However, uncertainties in market dynamics and vague management responses on policy impacts create a neutral sentiment. The lack of a market cap and mixed financial performance suggest a neutral stock price movement within -2% to 2%.
Delcath Systems, Inc. (DCTH) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call presents mixed signals: a slight revenue increase, improved gross margins, and significant R&D investments, but decreased net income and higher expenses. The guidance reflects slower site activations and a modest revenue outlook. The Q&A highlighted uncertainties in trial timelines and utilization impacts. Despite strong gross margins and promising trials, the inability to overshoot site guidance and potential revenue step-downs suggest limited short-term stock movement, leading to a neutral sentiment.
Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript
Unknown8-6
The earnings call presents a mixed picture. While financial performance shows improved profitability and gross margins, increased R&D and administrative expenses raise concerns. The Q&A highlights uncertainties in the NDRA program's impact and the downward adjustment in site activation guidance, which tempers optimism. Despite strong cash reserves, these factors suggest a balanced outlook, leading to a neutral sentiment.
DCTH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
